Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Erik Lundgren spoke with Proactive's Stephen Gunnion about the company's second-quarter results, its leadership transition and the milestones set to shape the next phase of its multiple sclerosis (MS) programme. Lundgren explained why he joined Immunic, pointing to the potential of lead candidate vidofludimus calcium and the chance to lead the business into two pivotal Phase 3 readouts. Lundgren flagged another key goal: launching a Phase 3 study in progressive MS before year-end. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy#Immunic #MultipleSclerosis #MS #Biotech #Biotechnology #ClinicalTrials #Phase3 #VidofludimusCalcium #Healthcare #DrugDevelopment #Nasdaq #Investing #Biopharma #ProactiveInvestors